HLB Innovation: 2025 Consolidated Operating Loss Widens to KRW 37.6B, Separate Entity Turns Profitable; Issued KRW 33B CB for Bio R&D Funding

Consolidated revenue in 2025: KRW 32.3B (up 27% YoY), but operating loss expanded to KRW 37.6B due to increased R&D (KRW 42.8B) and stock compensation costs (KRW 4.8B)
Separate (parent) net income turned positive to KRW 3.0B (vs loss of KRW 3.8B in 2024), mainly from fair value gain of KRW 3.1B on HLB convertible bond
Issued 3rd series convertible bond of KRW 33B in Jan 2025 (coupon 0%, maturity 2028); proceeds used for Verismo subsidiary equity acquisition and operating funds
Increased stake in Verismo Therapeutics to 98.75%; additional investments of KRW 32.8B during 2025 (quarterly installments)
Total CB outstanding: KRW 35.4B; conversion price for 3rd CB at KRW 1,917; potential dilution of up to 17.2M shares
Treasury shares: 7,024 shares (0.005%); no buyback or cancellation plans. No dividends
HLB group's ownership increased to 38.17% (from 36.25%), maintaining control stability
Auditor: Han Young Accounting Corp., unqualified opinion; key audit matters: impairment of investment in Verismo and goodwill impairment test
[AI Summary]Despite steady semiconductor growth and bio subsidiary clinical progress, HLB Innovation's consolidated net loss expanded to KRW 33.7B due to surging R&D costs. The CB issuance provides necessary funding for R&D but poses dilution risk for existing shareholders when converted.